Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dengue Tetravalent Vaccine (TDV)
Dengue Tetravalent Vaccine · 1 trial · 1 indication
GMTs for HPV were measured by immunoglobulin G binding assay (IgGBA) assay. HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 were the types of HPV analyzed.
| Arm | Type | Description |
|---|---|---|
| 9vHPV+TDV | EXPERIMENTAL | Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6). |
| 9vHPV | EXPERIMENTAL | Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6). |
| Name | Type | Description |
|---|---|---|
| 9vHPV Vaccine | BIOLOGICAL | 9vHPV intramuscular injection |
| Dengue Tetravalent Vaccine (TDV) | BIOLOGICAL | TDV subcutaneous injection |
Inclusion Criteria: 1. Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator. 2. Participants who can comply with trial procedures and are available for th...
Dengue Tetravalent Vaccine (TDV) is an investigational vaccine developed by Takeda Pharmaceutical Company Limited for the prevention of dengue fever. It is designed to protect against dengue, a mosquito-borne viral infection. TDV has been studied in a Phase 3 clinical trial in Thailand involving 614 healthy participants aged 9 to under 15 years.
Dengue Tetravalent Vaccine (TDV) is being developed for the prevention of dengue fever, an infectious disease caused by dengue virus. The vaccine is intended for use in healthy individuals, including adolescents and children. Its clinical program has focused on participants aged 9 to under 15 years in Thailand.
Dengue Tetravalent Vaccine (TDV) is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical development program for this vaccine candidate.
Dengue Tetravalent Vaccine (TDV) is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 3 trial evaluating TDV has been completed.
Dengue Tetravalent Vaccine (TDV) has been evaluated in a Phase 3 trial, NCT04313244, titled "Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years." The trial enrolled 614 participants in Thailand and is completed.
Yes, Dengue Tetravalent Vaccine is also known as Dengue Tetravalent Vaccine (TDV), often shortened to TDV. Both names refer to the same investigational vaccine developed by Takeda Pharmaceutical Company Limited for dengue fever prevention.